Journal article · 2026 · Open access

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial

Ying Fan, Yunjiang Liu, Yongsheng Wang, Quchang Ouyang, Qingyuan Zhang, Jiuwei Cui, Jingruo Li, Qiang Ding, Xinhong Wu, Xiaojia Wang, Zhongsheng Tong, Yinduo Zeng and 18 more

JAMA · Published 23 October 2026 · DOI 10.1001/jama.2026.21372

Open full textView at the publisherCite this paper

In brief

“Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial” is a 2026 journal article by Ying Fan and 29 co-authors, published in JAMA. OpenAlex counts 1 citations as of 18 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.15
References
23
Authors
30

Abstract

Importance: Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer. Objective: To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients with ERBB2-low metastatic breast cancer. Design, Setting, and Participants: This open-label, randomized, multicenter phase 3 trial was conducted at 73 hospitals across China. Eligible patients were females aged 18 to 75 years with centrally confirmed ERBB2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-negative) unresectable locally recurrent or metastatic breast cancer who had received 1 or fewer prior lines of chemotherapy for metastatic disease, with prior endocrine therapy required for hormone receptor-positive disease. Enrollment began on June 30, 2023, and ended on August 20, 2025. The last day of follow-up for the final analysis for progression-free survival in the current study was March 20, 2026. Interventions: Patients were randomly assigned (1:1) to receive trastuzumab rezetecan (6.4 mg/kg intravenously every 3 weeks; n = 277) or physician's choice of chemotherapy (n = 274). Main Outcomes and Measures: The primary end point was progression-free survival assessed by blinded independent central review in chemotherapy-naive patients and the overall population. Results: Between June 30, 2023, and August 20, 2025, a total of 551 patients were randomized, with a mean (SD) age of 54.9 (9.9) years. At the data cutoff (March 20, 2026), trastuzumab rezetecan significantly prolonged progression-free survival compared with chemotherapy in the chemotherapy-naive patients (median, 16.6 [95% CI, 14.0-19.4] months vs 6.8 [95% CI, 5.7-7.0] months; hazard ratio, 0.25 [95% CI, 0.19-0.33]; P < .001) and the overall population (median, 16.4 [95% CI, 14.0-16.8] months vs 6.8 [95% CI, 5.7-6.9] months; hazard ratio, 0.27 [95% CI, 0.21-0.34]; P < .001). The benefit was consistent in hormone receptor-negative disease (median progression-free survival: 16.5 vs 6.8 months; hazard ratio, 0.34, [95% CI, 0.22-0.54]) and hormone receptor-positive disease (median progression-free survival: 16.4 vs 6.7 months; hazard ratio, 0.24 [95% CI, 0.18-0.33]). Grade 3 or greater treatment-related adverse events occurred in 84.1% of patients (232/276) with trastuzumab rezetecan and 67.9% (184/271) with chemotherapy, most commonly decreased neutrophil count (180 [65.2%] vs 147 [54.2%]). Conclusions and Relevance: Trastuzumab rezetecan provided significant progression-free survival benefit over physician's choice of chemotherapy in patients with ERBB2-low advanced breast cancer, with benefit observed across all key subgroups. It exhibited the potential as a new treatment option with a distinct safety profile in this setting. Trial Registration: ClinicalTrials.gov Identifier: NCT05814354.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Fan, Y., Liu, Y., Wang, Y., Ouyang, Q., Zhang, Q., Cui, J., Li, J., Ding, Q., Wu, X., Wang, X., Tong, Z., Zeng, Y., Wang, W., Yan, M., Wang, Y., Liu, X., Li, K., Sun, Z., Yuan, C., . . . Xu, B. (2026). Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.21372

MLA 9

Fan, Ying, et al. “Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.21372.

Chicago

Fan, Ying, Yunjiang Liu, Yongsheng Wang, Quchang Ouyang, Qingyuan Zhang, Jiuwei Cui, Jingruo Li, et al. 2026. “Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.21372.

Harvard

Fan, Y. et al. (2026) ‘Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.21372.

IEEE

Y. Fan et al., “Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.21372.

BibTeX

@article{fan2026trastuzumab,
  title     = {{Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial}},
  author    = {Fan, Ying and Liu, Yunjiang and Wang, Yongsheng and Ouyang, Quchang and Zhang, Qingyuan and Cui, Jiuwei and Li, Jingruo and Ding, Qiang and Wu, Xinhong and Wang, Xiaojia and Tong, Zhongsheng and Zeng, Yinduo and Wang, Wenhui and Yan, Min and Wang, Yili and Liu, Xiaoyu and Li, Kai and Sun, Zhengkui and Yuan, Chunxiu and Wang, Ting and Xie, Weimin and Yao, Jing and Zhou, Shoubing and Hou, Jialin and Ouyang, Zhong and 李怡婧 and Cui, Sisi and Zhang, Xia and Zhu, Xiaoyu and Xu, Binghe},
  journal   = {JAMA},
  year      = {2026},
  doi       = {10.1001/jama.2026.21372},
  url       = {https://doi.org/10.1001/jama.2026.21372}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research

  • HER2-low metastatic breast cancer
  • HER2-targeted therapy
  • progression-free survival
  • chemotherapy comparison
  • HER2 immunohistochemistry
  • HER2 in situ hybridization
  • locally recurrent breast cancer
  • hormone receptor-positive breast cancer

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Fan, Y., Liu, Y., Wang, Y., Ouyang, Q., Zhang, Q., Cui, J., Li, J., Ding, Q., Wu, X., Wang, X., Tong, Z., Zeng, Y., Wang, W., Yan, M., Wang, Y., Liu, X., Li, K., Sun, Z., Yuan, C., . . . Xu, B. (2026). Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.21372

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Ying Fan, Yunjiang Liu, Yongsheng Wang, Quchang Ouyang, Qingyuan Zhang, Jiuwei Cui, Jingruo Li, Qiang Ding, Xinhong Wu, Xiaojia Wang, Zhongsheng Tong, Yinduo Zeng and 18 more.

What is the DOI of this paper?

10.1001/jama.2026.21372, permanently at https://doi.org/10.1001/jama.2026.21372. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.